Literature DB >> 31847725

Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology.

Michelle Curran1,2, Maelle Mairesse1, Alba Matas-Céspedes1,2, Bethany Bareham2, Giovanni Pellegrini3, Ardi Liaunardy4, Edward Powell2, Rebecca Sargeant1, Emanuela Cuomo4, Richard Stebbings1, Catherine J Betts1, Kourosh Saeb-Parsy2.   

Abstract

Significant advances in immunotherapies have resulted in the increasing need of predictive preclinical models to improve immunotherapeutic drug development, treatment combination, and to prevent or minimize toxicity in clinical trials. Immunodeficient mice reconstituted with human immune system (HIS), termed humanized mice or HIS mice, permit detailed analysis of human immune biology, development, and function. Although this model constitutes a great translational model, some aspects need to be improved as the incomplete engraftment of immune cells, graft versus host disease and the lack of human cytokines and growth factors. In this review, we discuss current HIS platforms, their pathology, and recent advances in their development to improve the quality of human immune cell reconstitution. We also highlight new technologies that can be used to better understand these models and how improved characterization is needed for their application in immuno-oncology safety, efficacy, and new modalities therapy development.

Entities:  

Keywords:  alternative models in toxicology; animal models; cancer; humanized mice; immune system; immunopathology; immunotoxicity; preclinical safety-assessment/risk management

Mesh:

Substances:

Year:  2019        PMID: 31847725     DOI: 10.1177/0192623319886304

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

1.  Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors.

Authors:  Richard Graveline; Morad Haida; Carolyne Dumont; Dominic Poulin; Florence Poitout-Belissent; Rana Samadfam; Sven Kronenberg; Franziska Regenass-Lechner; Rodney Prell; Marie-Soleil Piche
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

2.  Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Authors:  Laura J Janke; Denise M Imai; Heather Tillman; Rosalinda Doty; Mark J Hoenerhoff; Jiajie J Xu; Zachary T Freeman; Portia Allen; Natalie Wall Fowlkes; Ilaria Iacobucci; Kirsten Dickerson; Charles G Mullighan; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

Review 3.  Humanized Mouse Models for the Study of Periodontitis: An Opportunity to Elucidate Unresolved Aspects of Its Immunopathogenesis and Analyze New Immunotherapeutic Strategies.

Authors:  Carolina Rojas; Michelle P García; Alan F Polanco; Luis González-Osuna; Alfredo Sierra-Cristancho; Samanta Melgar-Rodríguez; Emilio A Cafferata; Rolando Vernal
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

4.  Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndrome.

Authors:  Alba Matas-Céspedes; Lee Brown; Krishnaa T Mahbubani; Bethany Bareham; Jackie Higgins; Michelle Curran; Lolke de Haan; Jean-Martin Lapointe; Richard Stebbings; Kourosh Saeb-Parsy
Journal:  Clin Transl Immunology       Date:  2020-11-04

Review 5.  Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies.

Authors:  Bethany Bareham; Nikitas Georgakopoulos; Alba Matas-Céspedes; Michelle Curran; Kourosh Saeb-Parsy
Journal:  Cancer Immunol Immunother       Date:  2021-04-08       Impact factor: 6.968

Review 6.  Immunological considerations and challenges for regenerative cellular therapies.

Authors:  Sandra Petrus-Reurer; Marco Romano; Sarah Howlett; Joanne Louise Jones; Giovanna Lombardi; Kourosh Saeb-Parsy
Journal:  Commun Biol       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.